Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) is anticipated to release its Q4 2024 earnings data after the market closes on Thursday, February 13th. Analysts expect Pacific Biosciences of California to post earnings of ($0.20) per share and revenue of $40.68 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biotechnology company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). Pacific Biosciences of California had a negative return on equity of 42.71% and a negative net margin of 227.69%. During the same quarter last year, the company posted ($0.27) earnings per share. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pacific Biosciences of California Price Performance

NASDAQ:PACB traded up $0.37 during trading hours on Friday, hitting $1.85. 45,822,557 shares of the stock were exchanged, compared to its average volume of 12,478,404. Pacific Biosciences of California has a 52-week low of $1.16 and a 52-week high of $6.83. The firm's fifty day moving average price is $1.80 and its 200 day moving average price is $1.79. The company has a current ratio of 9.74, a quick ratio of 8.64 and a debt-to-equity ratio of 1.97. The company has a market cap of $506.64 million, a P/E ratio of -1.27 and a beta of 1.92.

Insider Activity at Pacific Biosciences of California

In other Pacific Biosciences of California news, insider Oene Mark Van sold 34,405 shares of the company's stock in a transaction on Friday, January 10th. The stock was sold at an average price of $2.03, for a total transaction of $69,842.15. Following the transaction, the insider now directly owns 1,597,454 shares in the company, valued at $3,242,831.62. This represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have commented on PACB. Stephens reiterated an "overweight" rating and set a $2.50 price objective on shares of Pacific Biosciences of California in a research note on Friday. StockNews.com upgraded Pacific Biosciences of California to a "sell" rating in a report on Friday. Piper Sandler boosted their target price on Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a "neutral" rating in a report on Monday, November 11th. Scotiabank lowered their target price on Pacific Biosciences of California from $7.00 to $6.00 and set a "sector outperform" rating on the stock in a report on Monday, November 11th. Finally, UBS Group cut Pacific Biosciences of California from a "buy" rating to a "neutral" rating and set a $2.00 target price on the stock. in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Pacific Biosciences of California currently has a consensus rating of "Hold" and an average target price of $2.85.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.